Carisma Therapeutics (NASDAQ:CARM) Price Target Cut to $5.00 by Analysts at HC Wainwright

Carisma Therapeutics (NASDAQ:CARM) had its price objective cut by HC Wainwright from $8.00 to $5.00 in a report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, EF Hutton Acquisition Co. I upgraded Carisma Therapeutics to a “strong-buy” rating in a report on Wednesday, October 30th.

Carisma Therapeutics Trading Up 2.8 %

Shares of CARM opened at $0.85 on Monday. Carisma Therapeutics has a 1-year low of $0.80 and a 1-year high of $3.16. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. The firm’s 50-day moving average price is $0.97 and its 200-day moving average price is $1.10. The firm has a market capitalization of $35.29 million, a price-to-earnings ratio of -0.54 and a beta of 1.49.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. The business had revenue of $3.39 million for the quarter. Sell-side analysts anticipate that Carisma Therapeutics will post -1.33 EPS for the current year.

Hedge Funds Weigh In On Carisma Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Wexford Capital LP boosted its position in shares of Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Carisma Therapeutics during the second quarter valued at $40,000. Barclays PLC boosted its holdings in Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after acquiring an additional 549,290 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Carisma Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock worth $3,587,000 after acquiring an additional 11,200 shares during the last quarter. Institutional investors own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.